GlassScriptPhysician profile
Natasha Banerjee
NPI 1356668065
$2,941.88
in general payments reported to CMS, 2019-2025
20 companies · $54.67 in 2025
The $54.67 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $679 · 2022: $265 · 2024: $1,943 · 2025: $54.67.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,943 · Education: $30.65 · Food and Beverage: $24.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,942.50 |
| Education | $30.65 |
| Food and Beverage | $24.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,942.50 | 2024 | |
| Seagen INC. | $141.47 | 2019 | |
| Lilly USA, LLC | $138.92 | 2019 | |
| Abbvie INC. | $125.00 | 2022 | |
| Intuitive Surgical, INC. | $115.46 | 2022 | |
| Novartis Pharmaceuticals Corporation | $63.67 | 2019 | |
| Amgen INC. | $55.88 | 2019 | |
| Alexion Pharmaceuticals, INC. | $55.73 | 2019 | |
| Pfizer INC. | $46.47 | 2019-2025 | |
| United Therapeutics Corporation | $32.38 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $25.60 | 2019 | |
| Merck Sharp & Dohme LLC | $24.93 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $24.62 | 2019 | |
| Accord Healthcare, INC. | $24.02 | 2025 | |
| Genzyme Corporation | $22.68 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $22.66 | 2019 | |
| Eisai INC. | $22.50 | 2019 | |
| Puma Biotechnology, INC. | $20.15 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.57 | 2019 | |
| Incyte Corporation | $17.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natasha Banerjee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.